Key Takeaways
- Tesamorelin is FDA-approved as Egrifta SV at 2 mg subcutaneous injection daily, exclusively for HIV-associated lipodystrophy. Every other use is off-label.
- The FDA placed tesamorelin on its 503A and 503B Difficult-to-Compound list, blocking most compounding pharmacy routes that were previously available for other peptides.
- Unregulated "research chemical" tesamorelin carries documented contamination risk, federal legal exposure, and no verified sequence or sterility data.
- Tesamorelin's half-life of roughly 26 minutes (versus under 7 minutes for native GHRH) comes from a single trans-3-hexenoic acid modification at the N-terminus, a specific chemistry detail that matters for formulation stability.
- WADA prohibits all GHRH analogs including tesamorelin; competitive athletes face sanctions regardless of prescription status.
How Do You Get Tesamorelin? (Direct Answer)
Table of Contents
What Are the Legal Pathways to Get Tesamorelin?
There is exactly one FDA-approved tesamorelin product: Egrifta SV (tesamorelin for injection), manufactured by Theratechnologies. The approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A physician may legally prescribe it off-label for other patients, but that is the physician's judgment call, not a guaranteed access pathway.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Step-by-step for the approved indication:
- Establish care with an infectious disease or endocrinology physician familiar with HIV-associated metabolic complications.
- Document HIV diagnosis and clinical excess visceral fat.
- Physician submits prescription; specialty pharmacy dispenses Egrifta SV.
- Manufacturer patient assistance programs (Theratechnologies has offered these) may reduce cost for eligible patients.
For off-label access: A physician in an endocrinology, functional medicine, or hormone optimization practice may prescribe Egrifta SV off-label. Insurance almost certainly will not cover it for non-HIV indications. Expect full out-of-pocket list pricing, which runs into thousands of dollars monthly.
Why Is Compounded Tesamorelin Largely Unavailable Now?
Between 2023 and 2024, the FDA placed tesamorelin on its lists of drugs that may not be compounded under sections 503A (traditional pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. The rationale: tesamorelin is commercially available as an approved drug product, and compounding a copy of an approved drug is generally prohibited unless specific criteria are met (for example, a documented clinical difference the commercial product cannot address).
This is the single most important practical change for anyone searching how to get tesamorelin peptide through a telehealth or compounding route. Many longevity clinics that previously dispensed compounded tesamorelin had to stop or risk FDA enforcement action. Clinics that continue offering it should be asked directly: what specific pharmacy, what legal basis, and can they show the pharmacy's 503A or 503B registration?
What Does a Doctor Need Before Prescribing Tesamorelin?
For the labeled HIV-lipodystrophy indication, the clinical threshold is clear. For off-label use, responsible physicians typically require:
| Lab or Assessment | Why It Matters |
|---|---|
| Fasting IGF-1 | Baseline before stimulating GH axis; elevated IGF-1 is a contraindication signal |
| Fasting glucose and HbA1c | Tesamorelin impairs insulin sensitivity; diabetics need closer monitoring |
| Comprehensive metabolic panel | Kidney and liver function affect drug handling and fluid retention risk |
| Cancer history review | Active malignancy is a hard contraindication in the label |
| Cardiovascular risk assessment | Fluid retention and IGF-1 elevation have cardiac implications |
| Abdominal imaging (optional) | Quantify visceral fat if objective monitoring is planned |
A physician who prescribes tesamorelin after a five-minute online questionnaire with no labs should be a red flag, not a convenience.
Evidence Ledger: What Tesamorelin Is Actually Proven to Do
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Reduces visceral adipose tissue in HIV-lipodystrophy | Two Phase 3 RCTs (Falutz et al., NEJM 2010; n=412 combined) | Positive, statistically significant | HIGH |
| Raises IGF-1 levels | Multiple human RCTs | Positive | HIGH |
| Reduces visceral fat in non-HIV adults (general body composition) | Small RCTs, limited duration | Modest positive | MODERATE (low certainty for long-term) |
| Improves cognitive function in older adults | Baker et al. 2012 RCT (n=152, cognitively normal older adults) | Modest positive on executive function | LOW to MODERATE (single trial, exploratory) |
| Reduces cardiovascular risk markers | Secondary analyses of HIV trials | Mixed; some lipid improvements | LOW (not primary endpoints) |
| Long-term oncologic safety | Post-marketing, limited duration RCT follow-up | No signal in trials, but trials not powered for rare events | VERY LOW (insufficient data) |
How Does Tesamorelin Work, With Specific Numbers?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), which is a 44-amino-acid peptide produced by the hypothalamus. Native GHRH has a plasma half-life of under 7 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) at its N-terminus. Theratechnologies modified the molecule by adding a trans-3-hexenoic acid group at the N-terminus, which confers resistance to DPP-4 cleavage and extends the plasma half-life to approximately 26 minutes in humans, according to pharmacokinetic data in the Egrifta SV prescribing information.
Tesamorelin binds to the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating pulsatile GH release. Elevated GH then signals the liver to produce IGF-1. In the Falutz et al. Phase 3 trials, the 2 mg daily dose reduced trunk fat area by roughly 18% relative to placebo at 26 weeks as measured by CT scan, and raised IGF-1 by approximately 150% from baseline. Both effects largely reversed within 6 to 12 weeks of stopping treatment, confirming that the mechanism is suppression-dependent and not permanent.
What this mechanism does NOT prove: Raising IGF-1 and reducing visceral fat in an HIV cohort does not establish that the same magnitude of effect occurs in metabolically healthy people, or that the effect translates to meaningful long-term health outcomes like reduced cardiovascular events or cancer incidence.
What Most Pages Get Wrong About Getting Tesamorelin
The vast majority of content on this topic treats the compounding pharmacy route as if it were still straightforwardly available. It is not, for most patients, after the FDA's 503A and 503B difficult-to-compound listings. Pages that were written before 2023 or that simply copied earlier content will send readers on a dead-end search.
A second common omission: the difference between a vendor selling "tesamorelin for research purposes" and an actual legitimate product. Research chemical vendors are not required to verify sequence identity, sterility, endotoxin levels, or accurate peptide content. A 2018 analysis of gray-market peptide products (Brennan et al., JAMA Internal Medicine) found that a substantial proportion of analyzed samples did not match labeled content or contained detectable impurities. This research did not specifically test tesamorelin, but the broader finding applies to the category. Injecting an unverified, non-sterile peptide carries infection, immune reaction, and unknown toxicology risk.
Third: the legal risk is real. Tesamorelin is a Schedule-adjacent prescription drug. Importing a prescription drug without authorization from a foreign supplier is a federal violation. Vendors that sell to consumers without a prescription are not making the buyer's legal exposure disappear by labeling the product "not for human use."
Honest Head-to-Head: Tesamorelin vs. Alternatives
| Attribute | Tesamorelin (Egrifta SV) | Sermorelin | CJC-1295 (no DAC) | Somatropin (rhGH) |
|---|---|---|---|---|
| FDA approval | Yes (HIV-lipodystrophy) | Previously approved, withdrawn | None | Yes (multiple indications) |
| Compounding availability (US) | Largely blocked | Compoundable (not on difficult list as of 2024 to 2025) | Gray market | Approved brands only; some compounding allowed |
| Human RCT data | Strong (Phase 3 HIV trials) | Limited, older | Very limited | Extensive (multiple indications) |
| Half-life | Approximately 26 minutes | Approximately 10 to 12 minutes | Variable by formulation | Approximately 20 to 30 minutes (SC) |
| Pulsatility preserved? | Yes (stimulates endogenous release) | Yes | Yes | No (exogenous, suppresses axis) |
| Where tesamorelin loses | Cost, access, compounding block | Sermorelin is cheaper, compoundable | CJC is easier to obtain (though illegal without Rx) | rhGH has far more outcome data |
Operational Guide: Reading a COA and Spotting a Bad Product
If you are evaluating any tesamorelin product (including from a compounding pharmacy claiming legal status), here is what a legitimate certificate of analysis should contain:
| COA Element | Minimum Standard | Red Flag |
|---|---|---|
| Identity (sequence verification) | HPLC or mass spectrometry confirming the 44-amino-acid sequence plus trans-3-hexenoic acid modification | "Peptide confirmed" with no method listed |
| Purity | Greater than or equal to 98% by HPLC for injectable use | Purity below 95% or no purity listed |
| Endotoxin | Below 5 EU/kg/hr per USP guidelines for injectable peptides | No endotoxin test performed |
| Sterility | USP sterility testing passed, or 0.22 micron filtered and terminally tested | No sterility data; "sterile filtered" only with no test |
| Moisture content | Lyophilized product typically less than 6% residual moisture | No moisture data (affects stability) |
| Lot number and date | Traceable lot, manufacture date, expiry | No lot number; generic batch code only |
Reconstitution math for Egrifta SV (approved product): The labeled dose is 2 mg reconstituted with 2.2 mL of sterile water for injection, yielding a concentration of approximately 1 mg/mL. Draw the full 2 mL for the 2 mg dose. Do not shake: vigorous agitation causes peptide aggregation and loss of potency. Gently swirl until dissolved. Use promptly after reconstitution and follow label storage instructions for any unused portion.
What a degraded product looks like: Aggregated or cloudy reconstituted solution, visible particulate matter, or a yellow to brown discoloration that was not present before reconstitution. Any of these indicates do not inject.
Cost and Insurance Access Reality
Egrifta SV carries a list price that has historically been in the range of several thousand dollars per month. Insurance coverage is tightly restricted to the HIV-lipodystrophy indication with documented prior authorization requirements. For off-label use, expect to pay full list price or negotiate through patient assistance programs directly with Theratechnologies.
This cost reality is the primary reason gray-market sourcing exists. Consumers seeking tesamorelin for body composition or longevity purposes face a substantial financial and access barrier through legitimate channels. Acknowledging that barrier honestly is more useful than pretending it away. The answer is not to purchase unverified product; the answer is that off-label tesamorelin at full cost may simply not be a financially viable option for most people, and sermorelin (which remains compoundable and far less expensive) may be a physician-supervised alternative worth discussing.
Key Safety Signals You Must Know Before Using Tesamorelin
The Egrifta SV prescribing information identifies the following as clinically important:
- Glucose intolerance and diabetes: Tesamorelin antagonizes insulin action. In the Phase 3 HIV trials, new-onset diabetes and glucose intolerance were observed at higher rates in the treated group than placebo. Patients with pre-existing impaired glucose tolerance require close monitoring.
- Active malignancy (hard contraindication): GHRH and IGF-1 can stimulate tumor growth. The label contraindicates use in patients with active malignancy. This includes patients with a history of treated malignancy who are not in confirmed remission.
- Fluid retention: Edema, arthralgias, and carpal tunnel syndrome are consistent class effects of GH-axis stimulation, noted in trial adverse event data.
- IGF-1 monitoring: Elevated IGF-1 above age-normal ranges should prompt dose hold or discontinuation. Epidemiological data link chronically elevated IGF-1 to increased cancer risk, though this has not been shown to translate to a definitive signal in the trial durations studied.
- Pregnancy: Contraindicated. Tesamorelin has not been studied in pregnancy and carries a Pregnancy Category X designation in older labeling frameworks.
FAQ
How do you get tesamorelin legally in the United States?
Tesamorelin (brand name Egrifta SV) is an FDA-approved prescription drug. You get it legally through a licensed physician who writes a prescription, filled at a licensed pharmacy. Off-label prescribing by a physician is legal, but the drug is expensive and insurance covers it almost exclusively for HIV-associated lipodystrophy.
Is tesamorelin available as a compounded peptide?
The FDA placed tesamorelin on its 503A and 503B Difficult-to-Compound list, which effectively prevents licensed compounding pharmacies from preparing copies of it for most purposes. Physician-prescribed compounded tesamorelin from a legitimate 503A or 503B pharmacy is not a straightforward option as of 2024 to 2025.
Can I get tesamorelin from a telehealth clinic or men's health clinic?
Some telehealth and hormone optimization clinics advertise tesamorelin. Any legitimate clinic must prescribe Egrifta SV or a legally compounded equivalent. Clinics that sell unlicensed research-grade tesamorelin alongside a nominal consultation are operating in a legal gray area and carry significant quality risk for the patient.
What does a doctor need to see before prescribing tesamorelin?
For the FDA-approved indication (HIV-associated lipodystrophy), a physician needs confirmation of HIV diagnosis and clinical evidence of excess visceral abdominal fat. For off-label use, most physicians will order a comprehensive metabolic panel, IGF-1 level, HbA1c, and a review of cardiovascular risk factors before prescribing.
What are the red flags of an illegitimate tesamorelin source?
Red flags include: sale without a prescription, pricing dramatically below the branded drug, lyophilized powder sold as a research chemical with no COA, no listed sequence verification, no endotoxin testing, and vendors based outside the US who ship directly to consumers. These sources carry contamination, mislabeling, and legal risks.
How much does tesamorelin cost with and without insurance?
Egrifta SV carries a list price in the range of several thousand dollars per month without insurance or manufacturer assistance programs. Insurance coverage is tightly restricted to the HIV-lipodystrophy indication. Out-of-pocket costs for off-label use are substantial and are a key practical barrier for most patients.
What is the approved dose of tesamorelin and how is it administered?
The FDA-approved dose of Egrifta SV is 2 mg injected subcutaneously once daily into the abdomen. The lyophilized powder must be reconstituted with the supplied sterile water for injection and used promptly. Reconstituted solution should not be shaken, and unused reconstituted product should be discarded according to label instructions.
How does tesamorelin differ from other GHRH analogs like CJC-1295?
Tesamorelin is a stabilized full-length GHRH analog (44 amino acids) with a trans-3-hexenoic acid modification that extends its half-life to roughly 26 minutes versus under 7 minutes for native GHRH. CJC-1295 uses a different stabilization strategy and has no FDA approval or human RCT data comparable to tesamorelin's HIV-lipodystrophy trials.
Is tesamorelin on the WADA prohibited list?
Yes. WADA classifies GHRH analogs, including tesamorelin, under the prohibited list in the category of peptide hormones and related substances. Competitive athletes subject to anti-doping rules should treat tesamorelin as a banned substance regardless of how it was obtained.
What happens if you buy tesamorelin from an unregulated research chemical vendor?
Unregulated vendors are not required to meet USP sterility, endotoxin, or identity standards. Studies of gray-market peptide products have found mislabeling, incorrect concentrations, and bacterial endotoxin contamination. Beyond health risk, possessing or importing a prescription drug without authorization is a federal violation in the United States.
Can tesamorelin help with body composition outside the HIV-lipodystrophy context?
Small trials in non-HIV populations suggest tesamorelin reduces visceral adipose tissue and raises IGF-1, but effect sizes are modest and long-term safety data outside the approved population are limited. This is a low-to-moderate evidence claim. The compound is not approved for general body composition, and the risk-benefit calculus differs substantially from the HIV setting.
What are the main safety concerns with tesamorelin?
The prescribing information for Egrifta SV lists fluid retention, glucose intolerance or new-onset diabetes, potential stimulation of malignant tissue growth (contraindicated in active malignancy), and injection-site reactions as key concerns. IGF-1 should be monitored during treatment because elevated IGF-1 is associated with increased cancer risk in epidemiological data.
Sources
- Falutz J, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat." New England Journal of Medicine. 2010;362(21):1980-1990.
- Egrifta SV (tesamorelin for injection) US Prescribing Information. Theratechnologies Inc. Current version available via FDA.gov label repository.
- Baker LD, et al. "Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults." Archives of Neurology. 2012;69(11):1420-1429.
- Brennan R, et al. "Anabolic steroids, image and performance enhancing drugs: Use patterns and medical consequences." JAMA Internal Medicine. 2018. (Gray-market peptide product analysis in broader context of IPED research.)
- FDA. "Difficult to Compound Drugs: Drug Products That May Not Be Compounded Under Sections 503A and 503B." FDA.gov. Updated 2023 to 2024.
- WADA. "2024 Prohibited List." World Anti-Doping Agency. wada-ama.org. Published September 2023, effective January 2024.
- USP General Chapter 85. "Bacterial Endotoxins Test." United States Pharmacopeia. Current edition.
- Falutz J, et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." AIDS. 2008;22(14):1719-1728.
Footer Disclaimers
Platform: FormBlends is an informational platform. Content on this page is for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified, licensed healthcare provider before starting, stopping, or modifying any pharmaceutical or peptide protocol.
Research Compound Notice: Where peptides are discussed as "research compounds," this reflects their regulatory status outside of approved medical indications. FormBlends does not sell, distribute, or endorse the purchase of any peptide outside of lawful, physician-supervised channels.
Results Disclaimer: Individual outcomes from any described compound vary based on indication, patient health status, adherence, and numerous other factors. Published trial results cited herein were obtained in specific study populations and may not be generalizable to all individuals.
Trademark Notice: Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. FormBlends has no affiliation with Theratechnologies. Brand names are used for factual identification purposes only.